A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects
NCT ID: NCT03558425
Last Updated: 2018-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
41 participants
INTERVENTIONAL
2018-06-27
2018-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
NCT04703374
A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects
NCT05108038
A Study to Investigate the Effect of Food on the PK, PD of CKD-381 in Healthy Volunteers
NCT04830930
A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132
NCT04755985
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
NCT01043185
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TR group
Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
D026
1 tablet administered before the breakfast during 7 days
RT group
Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
CKD-381
1 tablet administered before the breakfast during 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-381
1 tablet administered before the breakfast during 7 days
D026
1 tablet administered before the breakfast during 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight more than 55kg
3. Body Mass Index more than 18.5 and under 25
Exclusion Criteria
2. Have a gastrointestinal disease history that can effect drug absorption or surgery.
3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of Investigational product, additives or benzimidazole family.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung Sang Yu, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Pharmacology and Therapeutics, Seoul Nat'l University College of Medicine and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul Nat'l University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
173BE18010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.